Reverse Transcriptase Inhibitors: all 1,328 studies that test it

Page 1 of 14. Open to participants first (42), then studies with results posted, then the rest; newest registration first within each.

• DOR/ISL in Pediatric Participants With HIV-1, <18 Years of Age and ≥ 35 kgNot yet recruitingNCT07862569Phase 2
• An Adaptive Platform Trial for Evaluation of Novel Treatment Regimens in Children and Adolescents With HIV in AfricaNot yet recruitingNCT07792096Phase 3
• Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 TreatmentRecruitingNCT07708727Phase 2/3
• Effectiveness and Safety of Darunavir/Cobicistat Plus Lamivudine Compared With Darunavir/Cobicistat Plus Tenofovir Alafenamide/Emtricitabine in Virologically Suppressed People Living With HIV at 24 and 48 Weeks of Follow-upRecruitingNCT07678268Phase 4
• Sleep Outcomes and Multidimensional Sleep Assessment - a Randomized Trial of Dolutegravir- vs Doravirine-based Antiretroviral Therapy in People Living With HIVNot yet recruitingNCT07673965Phase 4
• A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1RecruitingNCT07645287Phase 2
• Lamivudine as a Novel Clinical Effort for Rett SyndromeEnrolling by invitationNCT07640503Phase 2
• Comparative Trial Between Ainuovirine(ANV)/Lamivudine(3TC)/Tenofovir(TDF) and Efavirenz(EFV)/Lamivudine/Tenofovir RegimensNot yet recruitingNCT07631897Phase 4
• A Study of Ulonivirine (MK-8507) and Methadone in Healthy Volunteers (MK-8507-019)RecruitingNCT07595263Phase 1
• Efavirenz for the Treatment of Creutzfeldt-Jakob DiseaseRecruitingNCT07482085Phase 3
• REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidERecruitingNCT07476339Phase 4
• A Continued Access Study for Participants Transitioning From ViiV Healthcare-sponsored or ViiV Healthcare-collaborative Parent Studies for HIV TreatmentRecruitingNCT07393659Phase 3
• Efficacy and Safety of Doravirine in the Rapid InitiationRecruitingNCT07357584Phase 4
• A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)RecruitingNCT07266831Phase 2/3
• Efficacy, Safety, and ToLerability of Switching to A Two-Drug Regimen With DTG/3TC Compared to Maintaining A Three-Drug REgimen With BIC/FTC/TAF or DTG/3TC/ABC in ViroLogically SupprEssed PeopLe Living With HIV After 24 and 48 Weeks of Follow-UpRecruitingNCT07138144Phase 4
• Safety, Tolerability and Effectiveness of DTG/3TC vs BIC/TAF/FTC in PWH Without Antiretroviral ExperienceRecruitingNCT07031063Phase 4
• Effectiveness and Safety of Darunavir/Cobicistat Plus Lamivudine Versus Darunavir/Cobicistat Plus Tenofovir/Emtricitabine in Virologically Suppressed HIV-1-positive Individuals in MexicoRecruitingNCT06907056Phase 4
• The T Cell Activator of Cell Killing ("TACK") IT ON" STUDYRecruitingNCT06823596Not applicable
• PrEPsmart 2-1-1 PilotRecruitingNCT06631365Phase 2
• Change in Body Weight and BMI in PWH with DOR/3TC/TDF Compared with INSTIRecruitingNCT06602622Phase 4
• Antiviral Clinical Trial for Long Covid-19RecruitingNCT06511063Phase 2
• Antiviral Therapy in Infants With HBV InfectionNot yet recruitingNCT06503796Phase 4
• STARLITE for Unresectable High-Grade GliomasRecruitingNCT06428045Phase 1
• The Antiretroviral Speed Access Program Switch (ASAP-Switch) StudyNot yet recruitingNCT06375304Phase 4
• Efficacy and Tolerance of Abacavir/Lamivudine Treatment in Patients With Systemic Lupus ErythematosusNot yet recruitingNCT06356740Phase 2
• Tenofovir Disoproxil Fumarate in the Treatment of Parkinson's DiseaseRecruitingNCT06356662Phase 1
• Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV VirusesNot yet recruitingNCT06338826Phase 2
• A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV TreatmentsRecruitingNCT06337032Phase 4
• DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 InfectionRecruitingNCT06203132Phase 3
• Implementing Oral (Event-driven and Daily) and Long-acting Pre-Exposure Prophylaxis in Mobile Men in Sub-Saharan AfricaNot yet recruitingNCT06133686Phase 3
• Effects of Antiviral Therapies on Epstein-Barr Virus ReplicationEnrolling by invitationNCT05957913Phase 2
• Efficacy, Acceptability and Safety of Event-driven HIV PrEP Using TAF/FTC in MSM in Thailand and France.RecruitingNCT05813964Phase 3
• Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in PediatricsRecruitingNCT05674656Phase 1/2
• Optimizing Evidence-based HIV Prevention Targeting People Who Inject Drugs on PrEPRecruitingNCT05669534Phase 4
• Early Metabolic Effects of Antiretroviral Drugs in Healthy volUnteers: a Phase 2 Randomized StudyRecruitingNCT05652478Phase 2
• Ulonivirine (MK-8507) in Participants With Mild or Moderate Hepatic Impairment (MK-8507-014)Not yet recruitingNCT05093972Phase 1
• Reverse Triple Negative Immune Resistant Breast CancerRecruitingNCT05076682Phase 2
• Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung CancerRecruitingNCT04696575Phase 2
• HBsAg Seroclearance in Adults With HBV Related Liver Fibrosis After Receiving Combined Therapy of Peg-IFN and Tenofovir.RecruitingNCT04640129Phase 4
• Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of ADRecruitingNCT04500847Phase 1
• Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV RemissionRecruitingNCT02140255Phase 1/2
• Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)RecruitingNCT01419561Phase 2
• Efavirenz (EFV) IntensificationCompletedNCT07193875Phase 4Results posted
• Study of B/F/TAF in Participants Switching From CAB + RPV to B/F/TAF for HIV-1 Infection (EMPOWER)CompletedNCT06104306Phase 4Results posted
• A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAFCompletedNCT05911360Phase 3Results posted
• A Sub-study of Cabotegravir (CAB) and Rilpivirine (RPV) in Human Immunodeficiency Viruses (HIV)-Infected ParticipantsCompletedNCT05896761Phase 3Results posted
• Study to Assess the Effects of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injections Following Sub-cutaneous (SC) Administration Compared With Intramuscular (IM) Administration in Adult Participants Living With Human Immunodeficiency Virus (HIV-1) Infection in the FLAIR StudyCompletedNCT05896748Phase 3Results posted
• A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)Active, not recruitingNCT05631093Phase 3Results posted
• A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)Active, not recruitingNCT05630755Phase 3Results posted
• The Women TAF-FTC Benchmark StudyCompletedNCT05140954Phase 2/3Results posted
• The Women TDF-FTC Benchmark StudyCompletedNCT05057858Phase 2Results posted
• Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIVActive, not recruitingNCT05052996Phase 2Results posted
• Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV InfectionActive, not recruitingNCT04994509Phase 3Results posted
• Pre-Exposure Prophylaxis Study of Lenacapavir in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People at Risk for HIV InfectionActive, not recruitingNCT04925752Phase 3Results posted
• Dolutegravir-Lamivudine for naïve HIV-Infected Patients With ≤200 CD4/mm3CompletedNCT04880395Phase 4Results posted
• Project ADHERE: Clinical Proof-of-Concept of a Tenofovir (TFV) Aptamer-Based BiosensorCompletedNCT04870671Early Phase 1Results posted
• PrEP at a Syringe Services ProgramCompletedNCT04782180Phase 4Results posted
• Pre-Exposure Prophylaxis (PrEP)- Gender Affirming Hormone Therapy (GAHT) Interactions in TGWCompletedNCT04760691Phase 1Results posted
• Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024)TerminatedNCT04652700Phase 3Results posted
• Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)TerminatedNCT04644029Phase 3Results posted
• Drug-drug Interaction (DDI) Study of GSK3640254 With Darunavir/Ritonavir (DRV/RTV) and Etravirine (ETR)CompletedNCT04630002Phase 1Results posted
• Islatravir and Methadone Pharmacokinetics (MK-8591-029)CompletedNCT04568603Phase 1Results posted
• Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]CompletedNCT04564547Phase 2Results posted
• Pilot Study to Investigate the Safety and Feasibility of AntiRetroviral Therapy for Alzheimer's DiseaseCompletedNCT04552795Phase 1/2Results posted
• A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically SuppressedCompletedNCT04542070Phase 3Results posted
• Providing Suboxone and PrEP Using TelemedicineCompletedNCT04521920Not applicableResults posted
• Single-Dose Islatravir in Moderate Hepatic Impairment (MK-8591-030)CompletedNCT04515641Phase 1Results posted
• A Study of the Effect of a Moderate CYP3A Inducer Efavirenz on Quizartinib Pharmacokinetics in Healthy ParticipantsCompletedNCT04459598Phase 1Results posted
• Pharmacokinetic Study of Cabotegravir and Rilpivirine Long-acting Intramuscular Injections in Healthy Adult ParticipantsCompletedNCT04371380Phase 1Results posted
• Open Label Extension (OLE) of the TDF2 Study, BotswanaCompletedNCT04318210Not applicableResults posted
• Pharmacokinetics of Islatravir in Participants With Severe Renal Impairment (MK-8591-026)CompletedNCT04303156Phase 1Results posted
• Biomarkers for Event-driven PrEP AdherenceCompletedNCT04298697Phase 4Results posted
• Doravirine/Islatravir (DOR/ISL) in Pediatric Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are <18 Years of Age and Weigh ≥35 kg (MK-8591A-028)CompletedNCT04295772Phase 2Results posted
• Evaluating Drug Interactions Between Doravirine With Estradiol and Spironolactone in Healthy Transgender WomenCompletedNCT04283656Phase 1Results posted
• Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)CompletedNCT04233879Phase 3Results posted
• Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019)CompletedNCT04233216Phase 3Results posted
• Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)CompletedNCT04223791Phase 3Results posted
• Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With Other Antiretroviral Agents in People Living With HIVCompletedNCT04143594Phase 2Results posted
• Safety and Drug Detection Study of Dapivirine Vaginal Ring and Oral TRUVADA® in Breastfeeding Mother-Infant PairsCompletedNCT04140266Phase 3Results posted
• Study of Truvada for HIV Pre Exposure Prophylaxis Using Daily Directly Observed Therapy to Look at Potential Interactions Between Truvada and Hormone TherapyCompletedNCT04050371Phase 4Results posted
• Regimen Switch to Dolutegravir/Lamivudine Fixed Dose Combination From Current Antiretroviral Regimen in HIV-1 Infected and Virologically Suppressed Adults (SALSA)CompletedNCT04021290Phase 3Results posted
• A Study of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 Years) Who Are Virologically SuppressedCompletedNCT04012931Phase 2Results posted
• Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016)CompletedNCT04003103Phase 2Results posted
• Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Patients With Active Illicit Substance usECompletedNCT03998176Phase 4Results posted
• Randomized, Open Label Safety Trial of Dapivirine Vaginal Ring and Oral TRUVADA® Use in PregnancyCompletedNCT03965923Phase 3Results posted
• Study to Evaluate the Pharmacokinetics (PK), Safety, and Efficacy of B/F/TAF in Human Immunodeficiency Virus (HIV)-1 Infected, Virologically Suppressed, Pregnant Women in Their Second and Third TrimestersCompletedNCT03960645Phase 1Results posted
• Rapid Test and Treat Dolutegravir Plus Lamivudine Study in Newly Diagnosed Human Immunodeficiency Virus (HIV)-1 Infected AdultsCompletedNCT03945981Phase 3Results posted
• Quantification of Estradiol's Impact on Nucleotides in Cellular Populations of the Lower GI TractCompletedNCT03917420Phase 1Results posted
• Feasibility and Acceptability of Digital Pills to Monitor PrEP Adherence in MSM With Substance UseCompletedNCT03842436Phase 4Results posted
• Study to Evaluate the Effect of GSK3640254 on the Pharmacokinetics of Tenofovir Alafenamide/EmtricitabineCompletedNCT03836729Phase 1Results posted
• Evaluation of Pre-exposure Prophylaxis Cascade in Pregnant and Breastfeeding Women in Cape Town (Formative Study)CompletedNCT03826199Phase 4Results posted
• B/F/TAF Switch Study for HIV-HBV CoinfectionCompletedNCT03797014Phase 4Results posted
• Safety and Efficacy of Dolutegravir/Lamivudine (DTG/3TC) in Therapy-naive Human Immunodeficiency Virus-1 (HIV-1) Infected AdolescentsCompletedNCT03682848Phase 3Results posted
• The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifECompletedNCT03635788Phase 3Results posted
• Evaluating the Safety of and Adherence to a Vaginal Matrix Ring Containing Dapivirine and Oral Emtricitabine/Tenofovir Disoproxil Fumarate in an Adolescent and Young Adult Female PopulationCompletedNCT03593655Phase 2Results posted
• Arresting Vertical Transmission of Hepatitis B VirusCompletedNCT03567382Phase 4Results posted
• Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected AdultsCompletedNCT03547908Phase 3Results posted
• A Drug Interaction Study to Assess the Pharmacokinetics of Narlaprevir and Antiretroviral DrugsCompletedNCT03537404Phase 1Results posted
• B/F/TAF vs Atripla Double-Blind Switch Study in HIV-1 Infected AdultsTerminatedNCT03532425Phase 4Results posted
• Rapid HIV Treatment Initiation, Access and Engagement in CareCompletedNCT03512964Not applicableResults posted

← Reverse Transcriptase Inhibitors overview